Table 2 Frequency of intrathecal total IgG synthesis; oligoclonal IgG pattern; IgG CSF/serum ratios; intrathecal IgG fractions; absolute amount of locally produced IgG; and CSF and serum IgG concentrations
Units | Pattern I MS | Pattern II + III MS | Pattern II MS | Pattern III MS | AQP4-IgG+ NMO [48] | MOG-IgG+ EM [35] | |
|---|---|---|---|---|---|---|---|
CSF-restricted OCB | Samples | 15/17 (88.2) | 10/37 (27) | 9/25 (36) | 1/12 (8.3) | 29/177 (16.4) | 8/47 (17) |
CSF-restricted OCB | Patients | 8/10 (80) | 7/22 (31.8) | 6/16 (37.5) | 1/6 (16.7) | 22/80 (27.5) | 6/45 (13) |
CSF-restricted OCB, without transient OCB | Patients | 8/10 (80) | 5/22 (22.7) | 5/16 (31.3) | 0/6 (0) | 16/80 (20) | 6/45 (13) |
OCB, IEF pattern 1 | Samples | 2/15 (13.3) | 24/35 (68.6) | 13/23 (56.5) | 11/12 (91.7) | 127/177 (71.8) | n.d. |
OCB, IEF pattern 2 | Samples | 13/15 (86.7) | 7/35 (20) | 6/23 (26.1) | 1/12 (8.3) | 19/177 (10.7) | n.d. |
OCB, IEF pattern 3 | Samples | 0/15 (0) | 1/35 (2.9) | 1/23 (4.3) | 0/12 (0) | 10/177 (5.6) | n.d. |
OCB, IEF pattern 4 | Samples | 0/15 (0) | 1/35 (2.9) | 1/23 (4.3) | 0/12 (0) | 20/177 (11.3) | n.d. |
OCB, IEF pattern 5 | Samples | 0/15 (0) | 3/35 (8.6) | 2/23 (8.7) | 1/12 (8.3) | 1/177 (0.6) | n.d. |
QIgG > Qlim(IgG) | Patients | 3/10 (30) | 4/21 (19) | 4/14 (28.6) | 0/7 (0) | n.d. | n.d. |
QIgG > Qlim(IgG) | Samples | 7/17 (41.2) | 5/41 (12.2) | 5/24 (20.8) | 0/17 (0) | 13/143 (9) | n.d. |
QIgG, all LPs | – | 3.6 (1.9–9.35; 17) | 4.75 (1.3–21.5; 42) | 4.8 (1.3–21.5; 25) | 4.7 (1.98–12.6; 17) | 3.9 (0.2–58.1; 135) | n.d. |
QIgG, if positive | – | 3.63 (2.6–9.35; 7) | 5.03 (3.2–8.8; 5) | 5.03 (3.2–8.8; 5) | n.a. | 5.7 (2.5–58.1; 12) | n.d. |
IgGloc, all LPs | mg/L | 0 (0–75.76; 17) | 0 (0–51.17; 41) | 0 (0–51.17; 24) | 0 (0–0; 17) | 0 (0–441.4; 135) | n.d. |
IgGloc, QIgG positives | mg/L | 5.91 (2.31–75.76; 7) | 16.75 (11.79–51.17; 5) | 16.75 (11.79–51.17; 5) | n.a. | 13.9 (1.3–441.4; 12) | n.d. |
IgGIF, all LPs | % | 0 (0–0.58; 17) | 0 (0–0.59; 41) | 0 (0–0.59; 24) | 0 (0–0; 17) | 0 (0–90.6; 135) | n.d. |
IgGIF, QIgG positives | % | 0.14 (0.06–0.58; 7) | 0.47 (0.22–0.59; 5) | 0.47 (0.22–0.59; 5) | n.a. | 32.5 (2.8–90.6; 12) | n.d. |
IgG CSF, all LPs | mg/L | 39.9 (11–130; 17) | 43.7 (11.4–146; 41) | 46 (11.4–109; 24) | 37.7 (21–146; 17) | 37.9 (2.4–487; 136) | n.d. |
IgG CSF, QIgG positives | mg/L | 39.9 (16.8–130; 7) | 53.3 (22.9–109; 5) | 53.3 (22.9–109; 5) | n.a. | 70.6 (20.5–487; 12) | n.d. |
IgG serum, all LPs | g/L | 10 (3.9–28.04; 17) | 8.75 (5.55–28.9; 41) | 10.39 (5.55–24.8; 24) | 7.5 (6.15–28.9; 17) | 10 (1.9–55.8; 134) | n.d. |
IgG serum, QIgG positives | g/L | 9.21 (3.9–15.3; 7) | 8.75 (7.1–12.4; 5) | 8.75 (7.1–12.4; 5) | n.a. | 10.7 (2.4–18; 12) | n.d. |